None listed
Conditions
Interventions
None listed
Sponsors
The Catholic University of Korea, Yeouido St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Male or female who is at least 19 years of age and less than 60 years of age -Have clinical symptoms of central serous chorioretinopathy for more than 3 months -Best-corrected visual acuity (BCVA) of at least 20/200 as of the screening date according to the Snellen Chart (Snellen Snellen best-corrected visual acuity is converted to logMAR for statistical analysis) -Subretinal fluid (SRF) invading the central 3 mm ring zone is observed on OCT examination. -Fluorescein angiography (FA) demonstrates active focal leakage or diffuse leakage. Diffuse Leakage is observed on fluorescein angiography (FA) -Subjects who understand and voluntarily give written informed consent for this study
Exclusion criteria
Exclusion criteria: -Patients with other retinal diseases such as choroidal neovascularization, nodular choroidal vasculopathy, or choroidal neovascularization on diagnostic tests such as ocular optical coherence tomography angiography (OCT angiography). -If laser treatment is difficult due to cataracts or vitreous opacity -Retinal pigment epithelial atrophy with a diameter of 1000 µm or more within the 3 mm ring of the macula -Received laser or photodynamic therapy treatment in the macula for central serous chorioretinopathy, except for laser treatment in the periphery of the retina for retinal tears. -Have received oral or topical steroid treatment (periocular, sub-tenon, or intraocular) within the past year. -Received an intraocular injection of an anti-VEGF agent within the last 3 months, or have received a total of 3 or more anti-VEGF agent infusions, even if earlier. -Intraocular surgery, such as cataract or vitreous surgery, within the last 1 year -Patients who have taken medications for central serous chorioretinopathy such as acetazolamide or spironolactone within the past 6 months -Allergic to Fluorescein, a contrast agent used in fluorescein angiography (FA) or indocyanine green fluorescein angiography (ICG angiography). -Pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of central foveal thickness | — |
Secondary
| Measure | Time frame |
|---|---|
| Resolution rate of subretinal fluid;Changes of Best-Correted Visual Acuity | — |
Countries
Korea, Republic of
Contacts
Public ContactYoung Jung Roh
The Catholic University of Korea, Yeouido St. Mary's Hospital
Outcome results
None listed